Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Metformin is being compared to exercise and diet modifications. The researchers are
interested in learning if the addition of metformin to lifestyle modifications is more
helpful in treating the condition or disorder. Although metformin is FDA approved to treat
type 2 diabetes, it is not FDA approved for the treatment of Non-alcoholic fatty liver
(NAFLD) and is considered investigational for the purpose of this study.